Acquisition PotentialRecent biotech acquisitions suggest a 25-50% premium on PTGX's last closing price could be reasonable, indicating potential value in the acquisition.
Financial StabilityPTGX has a strong balance sheet, ending with total cash of $673.0M and a financial runway through at least YE28.
Potential Milestone PaymentsPTGX will be eligible for a $400M payment from Takeda if the company opts out of U.S. co-promotion of rusfertide, with potential milestone payments increasing to $975M.